Correction to: Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer

被引：0
|
作者：
Puneet Saxena
Pawan Kumar Singh
Prabhat Singh Malik
Navneet Singh
机构：
[1] Postgraduate Institute of Medical Education and Research (PGIMER),Department of Pulmonary Medicine
[2] University of Health Sciences,Department of Pulmonary and Critical Care Medicine, Post Graduate Institute of Medical Sciences (PGIMS)
[3] All India Institute of Medical Sciences,Department of Medical Oncology, Dr. B.R.A.I.R.C.H
来源：
Current Treatment Options in Oncology | 2020年 / 21卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The original version of this article unfortunately contained mistakes. In Table 2, under the column 'Lead to death' in Row 5 [CheckMate-026], the figures should read as '0.7' for Experimental Arm and '1.1' for Comparator. Right now, these are printed as 0.007 and 0.011 respectively.
引用
收藏
相关论文
共 50 条
  • [1] Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer
    Saxena, Puneet
    Singh, Pawan Kumar
    Malik, Prabhat Singh
    Singh, Navneet
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2020, 21 (08)
  • [2] Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer
    Puneet Saxena
    Pawan Kumar Singh
    Prabhat Singh Malik
    Navneet Singh
    Current Treatment Options in Oncology, 2020, 21
  • [3] Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer (vol 21, 69, 2020)
    Saxena, Puneet
    Singh, Pawan Kumar
    Malik, Prabhat Singh
    Singh, Navneet
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2020, 21 (11)
  • [4] First-line combination immunotherapy for metastatic non-small cell lung cancer
    Chen, Yuh-Min
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2020, 83 (05) : 433 - 441
  • [5] Pembrolizumab in Combination with Chemotherapy as First-Line Treatment of Advanced Non-Small Cell Lung Cancer
    Jahan, N.
    Swarup, S.
    Sultan, A.
    Naing, T.
    Mogollon-Duffo, F.
    Ball, S.
    Tun, A.
    Htut, T.
    Dash, A.
    D'Cunha, N.
    Hardwicke, F.
    Awasthi, S.
    Tijani, L.
    Thein, K.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S917 - S918
  • [6] Indirect comparison between immunotherapy alone and immunotherapy plus chemotherapy as first-line treatment for advanced non-small cell lung cancer: a systematic review
    Li, Lingling
    Xu, Fei
    Chen, Yu
    Ren, Xiaoli
    Liu, Yu
    Chen, Yuan
    Xia, Shu
    BMJ OPEN, 2020, 10 (11):
  • [7] Immunotherapy for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer
    Martinez, Pablo
    Peters, Solange
    Stammers, Timothy
    Soria, Jean-Charles
    CLINICAL CANCER RESEARCH, 2019, 25 (09) : 2691 - 2698
  • [8] Immunotherapy plus chemotherapy versus chemotherapy alone as first-line treatment for non-small cell lung cancer: A systematic review and meta-analysis.
    Abdelazeem, Basel
    Abbas, Kirellos Said
    Labieb, Fatma
    Arida, Abdul Karim
    El-Shahat, Nahla Ahmed
    Shehata, Joseph
    Kandah, Emad
    Malik, Bilal
    Akanbi, Maxwell Oluwole
    Rafae, Abdul
    Tahir, Nayha
    Wahab, Ahsan
    Ehsan, Hamid
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [9] First-line treatment for non-small cell lung cancer
    Pinn, Stephen
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2011, 72 (01) : 10 - 10
  • [10] Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small Cell Lung Cancer
    Wang, J.
    Lu, S.
    Hu, C.
    Sun, Y.
    Yang, K.
    Chen, M.
    Zhao, J.
    Yu, G.
    Zhou, X.
    Feng, G.
    Pan, Y.
    Yu, Y.
    Zhang, J.
    Liang, L.
    Lin, X.
    Cui, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S3 - S3
12345